Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study
- the Catholic Research Network for Multiple Myeloma (CAREMM-2102 study)
- Catholic Univ. of Korea Coll. Med.
Research output: Contribution to journal › Article › peer-review
3
Scopus
citations